Kashkooe Ali, Jalali Atefeh, Zarshenas Mohammad M, Hamedi Azadeh
Medicinal Plants Processing Research Center, Shiraz University of Medical Sciences, Shiraz 71468-64685, Iran.
Department of Phytopharmaceuticals (Traditional Pharmacy), School of Pharmacy, Shiraz University of Medical Sciences, Shiraz 71345-1583, Iran.
Biomedicines. 2024 Oct 10;12(10):2297. doi: 10.3390/biomedicines12102297.
The traditional use of (L.) Sch.Bip., commonly known as feverfew, extends across various medical conditions, notably those associated with pain and inflammation. In alignment with the growing trend towards developing medications that target specific signaling pathways for enhanced efficacy and reduced side effects, extensive research has been conducted to investigate and validate the pharmacological effects of feverfew. Among its bioactive compounds, parthenolide stands out as the most potent, categorized as a germacranolide-type sesquiterpene lactone, and has been extensively studied in multiple investigations. Significantly, the anti-inflammatory properties of feverfew have been primarily attributed to its capacity to inhibit nuclear factor-kappa B (NF-κB), resulting in a reduction in pro-inflammatory cytokines like tumor necrosis factor-alpha (TNF-α). Furthermore, the anticancer properties of feverfew have been associated with the modulation of Mitogen-Activated Protein Kinase (MAPK) and NF-κB signaling pathways. This study further delves into the neuroprotective potential of feverfew, specifically in the management of conditions such as migraine headaches, epilepsy, and neuropathic pain through various mechanisms. The core objective of this study is to elucidate the phytochemical composition of feverfew, with a particular emphasis on understanding the molecular mechanisms and examining the signaling pathways that contribute to its pharmacological and therapeutic effects. Additionally, the safety, toxicity, and potential adverse effects of feverfew are comprehensively evaluated, with an overarching goal of providing valuable insights into the plant's potential for targeted and effective treatments.
小白菊（Tanacetum parthenium (L.) Sch.Bip.），通常被称为 feverfew，其传统用途涵盖了各种医疗状况，尤其是与疼痛和炎症相关的那些。随着开发针对特定信号通路以提高疗效和减少副作用的药物这一趋势的不断发展，人们已进行了广泛研究来调查和验证小白菊的药理作用。在其生物活性化合物中，小白菊内酯最为突出，它被归类为吉马烷型倍半萜内酯，并且已在多项研究中得到广泛研究。值得注意的是，小白菊的抗炎特性主要归因于其抑制核因子-κB（NF-κB）的能力，从而导致肿瘤坏死因子-α（TNF-α）等促炎细胞因子的减少。此外，小白菊的抗癌特性与丝裂原活化蛋白激酶（MAPK）和 NF-κB 信号通路的调节有关。本研究进一步深入探讨了小白菊的神经保护潜力，特别是通过各种机制在偏头痛、癫痫和神经性疼痛等病症的管理方面。本研究的核心目标是阐明小白菊的植物化学成分，特别强调理解其分子机制并研究有助于其药理和治疗作用的信号通路。此外，还全面评估了小白菊的安全性、毒性和潜在不良反应，总体目标是为该植物在靶向和有效治疗方面的潜力提供有价值的见解。
